Safety Phase I Evaluation of MaaT033, a Lyophilized Full-ecosystem Gut Microbiota Delayed-release Capsule, In Hematologic Malignant Patients Under intensive Chemotherapy (CIMON)
Latest Information Update: 31 Jul 2023
At a glance
- Drugs MaaT 033 (Primary)
- Indications Acute myeloid leukaemia; Dysbiosis; Haematological malignancies; Myelodysplastic syndromes
- Focus Adverse reactions
- Acronyms CIMON
- Sponsors MaaT Pharma
Most Recent Events
- 27 Jul 2023 According to a MaaT Pharma media release, results from this trial were presented during the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2023) in April.
- 11 Apr 2023 According to a MaaT Pharma media release, results from this trial will be presented during the 49th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT 2023).
- 11 Apr 2023 Results presented in the MaaT Pharma media release.